--- title: "Vyome Holdings (HIND) news: reverse split, delisting and offering" url: "https://aibio.space/companies/vyome/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "HIND reverse split, delisting and offering news: ReShape Lifesciences (now Vyome Holdings) files NT 10-Q, delaying its first-quarter 10-Q." --- HIND Vyome Holdings, Inc. NASDAQ · United States # Vyome Holdings (HIND) news HIND reverse split, delisting and offering news Company Updates · 2026-08-28 ## [Vyome names Jerry Leonard chief financial officer](https://aibio.space/news/vyome-names-jerry-leonard-chief-financial-officer/) The board appointed Jerry Leonard as chief financial officer on August 27, 2026, effective September 1, 2026, under a consulting agreement with ClearbridgeCFO, LLC, after interim CFO Robert Dickey gave notice of his resignation. ## Latest Vyome Holdings news 1. 2026-05-28 Company Updates [Vyome reports first quarter 2026 results and an in-licensing agreement](https://aibio.space/news/vyome-reports-first-quarter-2026-results-licensing-agreement/) Vyome reported a net loss attributable to common shareholders of approximately $963,000 for the quarter ended March 31, 2026, and cash of approximately $8.8 million, while announcing an in-licensing agreement with Impetis Biosciences Limited, a TATA Enterprise. 2. 2025-06-18 Listings [ReShape Lifesciences (now Vyome Holdings) says equity tops Nasdaq $2.5 million minimum](https://aibio.space/news/reshape-lifesciences-now-vyome-holdings-says-equity-tops-nasdaq-2-5/) ReShape says sales under its at-the-market program and a June 9 offering have lifted its stockholders' equity above the $2.5 million Nasdaq minimum. The company says that does not guarantee it will stay listed. 3. 2025-05-30 Financings [ReShape Lifesciences (now Vyome Holdings) sets up $9,700,000 at-the-market program](https://aibio.space/news/reshape-lifesciences-now-vyome-holdings-sets-up-9-700-000-market/) Maxim Group LLC is the exclusive sales agent for up to $9,700,000 of stock, for a 3.0% commission. Two days earlier, Nasdaq had determined to delist ReShape, whose stockholders' equity was $1.2 million at March 31, 2025. 4. 2025-05-15 Distress [ReShape Lifesciences (now Vyome Holdings) files NT 10-Q, delaying its first-quarter 10-Q](https://aibio.space/news/reshape-lifesciences-now-vyome-holdings-files-nt-10-q-delaying-first/) The company says it needs more time to compile its financial statements for the quarter ended March 31, 2025, including to reflect the May 9, 2025 reverse stock split. 5. 2025-05-15 Distress [ReShape Lifesciences (now Vyome Holdings) delays first-quarter 10-Q](https://aibio.space/news/reshape-lifesciences-now-vyome-holdings-delays-first-quarter-10/) ReShape says a reverse stock split on May 9, 2025 is one reason its March quarter 10-Q needs more time. It expects to file within the five-day extension and says it does not expect a significant change in results. 6. 2025-04-01 Distress [ReShape Lifesciences (now Vyome Holdings) files NT 10-K late notice for 2024 annual report](https://aibio.space/news/reshape-lifesciences-now-vyome-holdings-files-nt-10-k-late-notice-2024/) ReShape Lifesciences filed a Form NT 10-K on April 1, 2025, saying it needs more time to compile information for its 2024 annual report. The notice does not explain the delay, and the company's 2023 annual report set a cost reduction target of about 55.4% for 2024. ## Vyome Holdings at a glance - **Ticker**: HIND - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $7.9 million ### Related companies - [Bicara Therapeutics](https://aibio.space/companies/bicara-therapeutics/) NASDAQ: BCAX - [Biohaven](https://aibio.space/companies/biohaven/) NYSE: BHVN - [Amneal Pharmaceuticals](https://aibio.space/companies/amneal-pharmaceuticals/) NASDAQ: AMRX - [Genprex](https://aibio.space/companies/genprex/) NASDAQ: GNPX - [Trafalgar International](https://aibio.space/companies/trafalgar-international/) OTC: TRFA - [Opus Genetics](https://aibio.space/companies/opus-genetics/) NASDAQ: IRD - [Verrica Pharmaceuticals](https://aibio.space/companies/verrica-pharmaceuticals/) NASDAQ: VRCA - [Protagonist Therapeutics](https://aibio.space/companies/protagonist-therapeutics/) NASDAQ: PTGX ### Also on NASDAQ - [PROCEPT BioRobotics](https://aibio.space/companies/procept-biorobotics/) PRCT - [Lifevantage](https://aibio.space/companies/lifevantage/) LFVN - [Candel Therapeutics](https://aibio.space/companies/candel-therapeutics/) CADL - [Amphastar Pharmaceuticals](https://aibio.space/companies/amphastar-pharmaceuticals/) AMPH - [Madrigal Pharmaceuticals](https://aibio.space/companies/madrigal-pharmaceuticals/) MDGL - [ImmunityBio](https://aibio.space/companies/immunitybio/) IBRX ## What Vyome Holdings does Vyome Holdings, Inc., formerly ReShape Lifesciences Inc., is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need. It completed a merger with Vyome Therapeutics, Inc. on August 15, 2025, and is based in Cambridge, MA, Princeton, NJ and New Delhi, India. Its lead program, VT-1953, is a topical gel being developed to treat signs and symptoms of malignant fungating wounds in advanced cancer. The company has announced positive results from a Phase 2 investigator-initiated trial and plans to hold discussions with the FDA on a pivotal Phase 3 trial design in the first half of 2026. VB1953, for moderate to severe acne, has completed its Phase II trial and is described as Phase 3-ready. VT-1908, an ophthalmic drops program for anterior uveitis, is at the pre-Investigational New Drug application stage. Its pharmaceutical segment has commercialized two topical antifungal products in India, a dandruff lotion and shampoo, sold under a licensing and marketing agreement with Sun Pharma Laboratories Limited. The company says it does not have any products approved for sale. | Product or program | What it is | Stage | |---|---|---| | VT-1953 | Topical gel for signs and symptoms of malignant fungating wounds in advanced cancer | positive Phase 2 investigator-initiated trial results | | VB1953 | Topical product for moderate to severe acne | Phase 3-ready | | VT-1908 | Eye drop for anterior uveitis, steroid-sparing | pre-Investigational New Drug application stage | | Antifungal dandruff lotion and shampoo | Reformulated topical antifungal products sold in India via Sun Pharma | commercialized in India | Summarised from the company's [10-K filed Mar 18, 2026](https://www.sec.gov/Archives/edgar/data/1427570/000121390026029500/ea0280821-10k_vyomehold.htm). ## Vyome Holdings annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$319,714](https://www.sec.gov/Archives/edgar/data/1427570/000121390026029500/) | [$256,944](https://www.sec.gov/Archives/edgar/data/1427570/000121390026029500/) | | Research and development | [$588,258](https://www.sec.gov/Archives/edgar/data/1427570/000121390026029500/) | [$285,391](https://www.sec.gov/Archives/edgar/data/1427570/000121390026029500/) | | Net income (loss) | [-$10.3 million](https://www.sec.gov/Archives/edgar/data/1427570/000121390026029500/) | [-$1.4 million](https://www.sec.gov/Archives/edgar/data/1427570/000121390026029500/) | | Cash from operations | [-$3.7 million](https://www.sec.gov/Archives/edgar/data/1427570/000121390026029500/) | [-$614,136](https://www.sec.gov/Archives/edgar/data/1427570/000121390026029500/) | | Cash and equivalents | [$5.0 million](https://www.sec.gov/Archives/edgar/data/1427570/000121390026088402/) | [$101,904](https://www.sec.gov/Archives/edgar/data/1427570/000121390026029500/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $7.9 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Vyome Holdings Did Vyome Holdings do a reverse stock split? Our latest story on this, dated May 15, 2025: "ReShape Lifesciences (now Vyome Holdings) files NT 10-Q, delaying its first-quarter 10-Q". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/reshape-lifesciences-now-vyome-holdings-files-nt-10-q-delaying-first/). Was Vyome Holdings delisted? Our latest story on this, dated May 30, 2025: "ReShape Lifesciences (now Vyome Holdings) sets up $9,700,000 at-the-market program". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/reshape-lifesciences-now-vyome-holdings-sets-up-9-700-000-market/). Has Vyome Holdings raised money recently? Our latest story on this, dated Jun 18, 2025: "ReShape Lifesciences (now Vyome Holdings) says equity tops Nasdaq $2.5 million minimum". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/reshape-lifesciences-now-vyome-holdings-says-equity-tops-nasdaq-2-5/). What is the ticker symbol of Vyome Holdings? Vyome Holdings, Inc. trades under the ticker HIND on NASDAQ. Where is Vyome Holdings listed? Vyome Holdings, Inc. is listed on NASDAQ. What is the SEC CIK of Vyome Holdings? The SEC Central Index Key (CIK) for Vyome Holdings, Inc. is 1427570. Its filings are on SEC EDGAR. How many shares does Vyome Holdings have outstanding? 7,018,528 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-12. Which country or territory is Vyome Holdings listed under? Our directory records Vyome Holdings, Inc. under United States. What does Vyome Holdings do? Our directory classifies Vyome Holdings, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Vyome Holdings? The ISIN recorded for Vyome Holdings, Inc. is US92943X1046. Does aibio.space cover Vyome Holdings? aibio.space lists Vyome Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Vyome Holdings incorporated? SEC records list its state or country of incorporation as DE. What does Vyome Holdings develop? Vyome Holdings, Inc., formerly ReShape Lifesciences Inc., is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need. It completed a merger with Vyome Therapeutics, Inc. on August 15, 2025, and is based in Cambridge, MA, Princeton, NJ and New Delhi, India. What is VT-1953 from Vyome Holdings? VT-1953: Topical gel for signs and symptoms of malignant fungating wounds in advanced cancer Stage: positive Phase 2 investigator-initiated trial results. What is VB1953 from Vyome Holdings? VB1953: Topical product for moderate to severe acne Stage: Phase 3-ready. ## Investor discussion: Vyome Holdings Members talk about Vyome Holdings (HIND). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Vyome Holdings, newest first. Each line links the filing it comes from. 1. 2026-03-18 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1427570/000121390026029500/ea0280821-10k_vyomehold.htm) 2. 2026-02-25 Financings Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1427570/000121390026020387/ea027793501ex99-1_vyome.htm) 3. 2025-11-06 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1427570/000121390025107166/ea0262701-s3_vyome.htm) 4. 2025-09-02 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1427570/000121390025082924/ea025487401ex99-1_vyome.htm) 5. 2025-08-20 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1427570/000121390025079042/ea0253965-424b5_vyome.htm) 6. 2025-08-20 Legal Reported a change of independent auditor. SEC Form 8-K (Items 1.01,4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1427570/000121390025079045/ea0253846-8k_vyome.htm) 7. 2025-08-19 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,3.02,3.03,5.02,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1427570/000121390025078603/ea0253813-8k_vyome.htm) 8. 2025-07-25 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1427570/000110465925070826/tm2521354d4_8k.htm) 9. 2025-06-18 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1427570/000110465925060706/tm2518350d1_8k.htm) 10. 2025-05-30 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1427570/000110465925054856/tm2516583d1_8k.htm) 11. 2025-05-30 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1427570/000110465925054876/tm2516583d2_8k.htm) 12. 2025-05-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1427570/000110465925049418/tm2515235d1_nt10q.htm) 13. 2025-05-09 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1427570/000110465925046717/tm2514338d1_ex99-1.htm) 14. 2025-04-21 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1427570/000110465925036837/tm2512794d1_8k.htm) 15. 2025-04-02 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1427570/000110465925030900/tm2511145d1_8k.htm) 16. 2025-04-01 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1427570/000110465925030540/tm2510990d1_nt10k.htm) 17. 2025-03-14 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1427570/000110465925023989/tm258078-2_def14a.htm) 18. 2025-03-03 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1427570/000110465925019794/tm258078d1_pre14a.htm) 19. 2025-02-20 Financings Reported a financing. SEC Form 8-K (Items 1.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1427570/000110465925015658/tm253570d16_ex99-1.htm) 20. 2025-01-21 Financings Reported a financing. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1427570/000110465925004648/rsls-20231231xs1.htm) 21. 2024-12-20 Financings Reported an unregistered sale of its securities. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1427570/000110465924130324/rsls-20231231xs1.htm) 22. 2024-12-11 Mergers Filed documents for a merger or acquisition. SEC Form 425. [Source](https://www.sec.gov/Archives/edgar/data/1427570/000110465924127478/tm2430703d2_425.htm) 23. 2024-12-02 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1427570/000110465924124568/tm2419158d7_8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:HIND on TradingView](https://www.tradingview.com/symbols/NASDAQ-HIND/). ## SEC filings and registration - **SEC name**: Vyome Holdings, Inc - **CIK**: 1427570 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: HIND (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 1001 CALLE AMANECER, SAN CLEMENTE, CA, 92673 - **Phone**: 949-429-6680 - **Shares outstanding**: 7,018,528 as of 2026-08-12 (10-Q filed 2026-08-12) - **Former names**: ReShape Lifesciences Inc.; OBALON THERAPEUTICS INC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1427570/000121390026095093/ea0303860-8k_vyome.htm) filed 2026-08-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1427570/000121390026093512/ea0303228-8k_vyome.htm) filed 2026-08-25 - [10-Q](https://www.sec.gov/Archives/edgar/data/1427570/000121390026088402/ea0300868-10q_vyome.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1427570/000121390026062458/ea0292643-8k_vyome.htm) filed 2026-05-29 - [10-Q](https://www.sec.gov/Archives/edgar/data/1427570/000121390026055058/ea0289466-10q_vyome.htm) filed 2026-05-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1427570/000121390026049312/ea0288267-8k_vyome.htm) filed 2026-04-29 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1427570/000121390026036740/ea0282811-02.htm) filed 2026-03-31 - [10-K](https://www.sec.gov/Archives/edgar/data/1427570/000121390026029500/ea0280821-10k_vyomehold.htm) filed 2026-03-18 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001427570), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Vyome Holdings, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker HIND, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Vyome Holdings, Inc. - **Ticker**: HIND - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US92943X1046 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-HIND/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/vyome/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Vyome Holdings (HIND) news: reverse split, delisting and offering", 2026-10-31, https://aibio.space/companies/vyome/